10-Q: Cue Biopharma Secures BI Deal, Faces Going Concern Doubt

Cue Biopharma reported a reduced net loss and secured a significant collaboration with Boehringer Ingelheim, but faces substantial doubt about its ability to continue as a going concern and a Nasdaq minimum bid deficiency.

Summary

• Net loss for the six months ended June 30, 2025, decreased to $20.7 million from $22.5 million in the prior year period.
• Collaboration revenue for the six months ended June 30, 2025, was $3.4 million, a decrease from $4.4 million in the prior year, primarily due to the termination of the Ono collaboration, partially offset by the new BI agreement.
• Research and development expenses decreased by $3.3 million to $16.5 million for the six months ended June 30, 2025, mainly due to reduced clinical trial costs for the CUE-100 series.
• Cash and cash equivalents stood at $27.5 million as of June 30, 2025.
• The company believes its existing cash will fund operations into the second quarter of 2026, but substantial additional capital is required, raising substantial doubt about its ability to continue as a going concern.
• A new Collaboration and License Agreement with Boehringer Ingelheim International GmbH (BI) was signed on April 10, 2025, for CUE-501, including an upfront payment of $10.1 million (net of $1.9 million German withholding taxes) and eligibility for up to $345.0 million in milestones plus royalties.
• The company is prioritizing its autoimmune programs, CUE-401 and the CUE-500 series, and plans to file an Investigational New Drug (IND) application for CUE-401 in the second quarter of 2026.
• The oncology CUE-100 series programs (CUE-101 and CUE-102) have been deprioritized, with the company actively seeking third-party support through partnerships for their further development.
• Clinical data for CUE-101 in HPV+ recurrent metastatic head and neck squamous cell carcinoma (HNSCC) showed an Overall Response Rate (ORR) of 50% in treatment-naive patients when combined with pembrolizumab, compared to 19% with pembrolizumab alone in historical trials.
• CUE-101 also demonstrated an 88% 12-month Overall Survival (OS) compared to 57% historically, and a median OS of 32 months compared to 12.3 months historically.
• The company received a Nasdaq deficiency letter on May 12, 2025, for failing to meet the minimum $1.00 bid price requirement, with a deadline of November 10, 2025, to regain compliance.
• The company amended its lease agreement on June 30, 2025, reducing the monthly rental rate from $235,884 to $147,546 and extending the term to April 14, 2028.
• Authorized common stock was increased to 300,000,000 shares on June 5, 2025.

Sentiment

Score: 4

Explanation: The sentiment is mixed to negative. While the Boehringer Ingelheim collaboration and promising CUE-101 clinical data are significant positives, the explicit 'going concern' warning, the Nasdaq delisting risk, and the ongoing need for substantial capital raise significant concerns about the company's financial stability and long-term viability. The deprioritization of oncology programs, despite strong data, also adds a layer of strategic uncertainty.

Positives

• Net loss decreased by $1.8 million for the six months ended June 30, 2025, compared to the prior year period.
• Net cash used in operating activities significantly improved, decreasing by $8.2 million to $11.6 million for the six months ended June 30, 2025.
• Secured a new Collaboration and License Agreement with Boehringer Ingelheim (BI) for CUE-501, including an upfront payment of $10.1 million and potential future milestones up to $345.0 million plus royalties.
• Strong clinical data for CUE-101 in HPV+ HNSCC, showing a 50% ORR (vs. 19% historical) and an 88% 12-month OS (vs. 57% historical) when combined with pembrolizumab.
• Reduced monthly rental rate for office and laboratory space from $235,884 to $147,546, effective June 30, 2025, and extended the lease term.
• Increased cash and cash equivalents to $27.5 million as of June 30, 2025, supported by recent financing activities.

Negatives

• Collaboration revenue decreased by $1.0 million for the six months ended June 30, 2025, compared to the prior year period.
• The company has incurred recurring losses and negative cash flows from operations since inception and has no history of generating commercial revenue.
• Substantial doubt exists regarding the company's ability to continue as a going concern, as existing cash is only expected to fund operations into the second quarter of 2026.
• Received a Nasdaq deficiency letter on May 12, 2025, for failing to meet the minimum $1.00 bid price requirement, risking delisting.
• The Collaboration and Option Agreement with Ono Pharmaceutical Co., Ltd. for CUE-401 was terminated effective March 6, 2025.
• The CUE-100 series oncology programs (CUE-101 and CUE-102) have been deprioritized, despite positive clinical data for CUE-101, indicating a shift away from internal development in oncology.

Risks

• Recurring losses from operations raise substantial doubt regarding the ability to continue as a going concern.
• No history of generating commercial revenue and may never achieve or maintain profitability.
• Currently no FDA-approved or commercialized products.
• Substantial dependence on the success of drug product candidates, with only two currently in clinical trials.
• Limited experience in conducting clinical trials and no history of commercializing biologic products.
• Success in preclinical studies or early clinical trials may not be indicative of results obtained in later trials.
• Inability to establish or benefit from collaborations or strategic alliances.
• Difficulty in identifying additional drug product candidates, and prioritization decisions may prove wrong.
• Significant competition from other biotechnology and pharmaceutical companies.
• Reliance on third parties to conduct clinical trials and manufacture drug supplies.
• Inability to protect intellectual property could adversely affect financial condition and value.
• Need for substantial additional financing, which may be difficult to obtain, restrict operations, or result in dilution.
• Loan agreement requires meeting certain operating covenants and places restrictions on operating and financial flexibility.
• Changes in and uncertainty surrounding U.S. trade policy could negatively impact costs, production, and supply chain.
• Changes in tax laws or their implementation/interpretation could adversely affect business and financial condition.
• Failure to comply with Nasdaq continued listing requirements could lead to delisting, negatively impacting stock price and ability to access capital markets.

Future Outlook

The company expects its existing cash and cash equivalents to fund operations into the second quarter of 2026. It plans to file an Investigational New Drug (IND) application for CUE-401 in the second quarter of 2026, with human proof-of-mechanism data anticipated in the first half of 2027. The company is actively seeking collaborations for its oncology assets (CUE-101 and CUE-102) to further exploit its technology platform in autoimmune disease and accelerate pipeline expansion. Substantial additional capital will be required to fund future operations, which the company expects to finance through equity offerings, collaborations, and other strategic alliances.

Management Comments

• Our Immuno-STAT platform is designed to selectively modulate disease-relevant T cells, enhancing efficacy while minimizing off-target effects.
• We believe our Immuno-STAT platform holds the promise of producing drug product candidates with the potential of establishing new standards of care in the treatment of autoimmune disease and cancer.
• We are prioritizing CUE-401 and the CUE-500 series, and are preparing to file an IND application for CUE-401 in the second quarter of 2026.
• We are actively seeking collaborations for our oncology assets CUE-101 and CUE-102 to allow us to more fully exploit the potential of our technology platform in the area of autoimmune disease and accelerate and expand our pipeline.
• We will need to raise additional capital to fund our future operations and remain as a going concern.

Industry Context

The company operates in the highly competitive biopharmaceutical industry, focusing on novel injectable therapeutics that selectively modulate disease-specific T cells. Its Immuno-STAT platform aims to differentiate itself from conventional approaches by enhancing efficacy and minimizing off-target effects, potentially establishing new standards of care in autoimmune disease and cancer. The strategic shift to prioritize autoimmune programs (CUE-401, CUE-500 series) aligns with a growing industry focus on precision immunology and targeted cell depletion, while seeking partnerships for oncology assets (CUE-100 series) reflects a common strategy for smaller biotechs to de-risk and fund programs through external collaborations.

Comparison to Industry Standards

• The CUE-101 Phase 1b study in HPV+ R/M HNSCC showed an Overall Response Rate (ORR) of 50% in treatment-naive patients treated with CUE-101 and KEYTRUDA (pembrolizumab) with combined positive score (CPS) ≥1, which compares favorably to an ORR of 19% observed with KEYTRUDA alone in the historical KEYNOTE-048 trial.
• The 12-month Overall Survival (OS) of 88% for CUE-101 combined with KEYTRUDA is significantly higher than the 57% observed with KEYTRUDA alone in the historical KEYNOTE-048 trial, representing a substantial reduction in the risk of death (hazard ratio of 0.23).
• The median OS of 32 months for CUE-101 combined with KEYTRUDA is notably longer than the 12.3 months reported in the historical KEYNOTE-048 trial.
• The 50% ORR in patients with low PD-L1 expression (CPS 1-19) suggests CUE-101's potential efficacy extends beyond high PD-L1 expressors, which is a key challenge in current immunotherapy standards.

Corporate Governance

Related Party Transactions

• The company has an ongoing license agreement with Albert Einstein College of Medicine (Einstein License) for its core technology platform. Payments include annual maintenance fees ($0.1 million annually) and milestone payments (up to $1.85 million per product/indication, and up to $5.75 million based on cumulative sales).
• In the second quarter of 2025, the company paid Einstein $0.9 million in fees related to the amendment of the Einstein License in connection with the BI Collaboration and License Agreement.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing and future equity offerings, as well as the potential for share price volatility due to the Nasdaq delisting threat and the 'going concern' warning.
• Employees may face uncertainty due to the company's 'going concern' status, although the BI collaboration and pipeline prioritization could offer long-term stability if successful.
• Customers (potential patients) could benefit from the continued development of novel therapeutics for autoimmune diseases and cancer, particularly if CUE-401 or CUE-501 achieve clinical success and regulatory approval.
• Creditors, particularly First Citizens Bank, are exposed to the company's financial health, with the loan agreement requiring specific covenants and full repayment by December 1, 2025.
• Suppliers and third-party contractors may face increased scrutiny or risk due to the company's 'going concern' status, potentially impacting terms of engagement.

Next Steps

• File an Investigational New Drug (IND) application for CUE-401 in the second quarter of 2026.
• Anticipate human proof-of-mechanism data for CUE-401 in the first half of 2027.
• Actively seek collaborations or strategic alliances to further develop the CUE-100 series oncology programs (CUE-101 and CUE-102).
• Monitor the closing bid price of common stock and evaluate options to regain compliance with Nasdaq's Minimum Bid Requirement by November 10, 2025.
• Continue to raise additional capital through equity offerings, collaborations, and other strategic alliances to fund future operations.

Key Dates

Recommendation

Despite promising early clinical data for CUE-101 and a significant collaboration with Boehringer Ingelheim, the company explicitly states 'substantial doubt' about its ability to continue as a going concern. This, coupled with the Nasdaq minimum bid price deficiency and the ongoing need for substantial additional capital, presents a high level of financial risk. While the BI deal provides some cash and validation, the fundamental viability of the company remains highly uncertain. Investors should consider selling to mitigate exposure to potential delisting, further dilution, or business failure.

Keywords

Biopharma, Autoimmune Disease, Cancer, Immuno-STAT, T cells, CUE-401, CUE-501, CUE-101, CUE-102, Boehringer Ingelheim, Nasdaq, Going Concern, Clinical Stage, Drug Development, Biologics